UNLABELLED: Upon vaccination, B cells differentiate into antibody secreting cells (ASCs) that migrate via the circulation to tissues. The kinetics of this response and the relationship of circulating ASCs to protective antibody titers have not been completely explored. METHODS: Influenza-specific and total-IgG ASCs were enumerated by Elispot and flow cytometry daily in the blood in 6 healthy adults after trivalent influenza vaccination (TIV). RESULTS: Peak H1-specific IgG ASC frequencies occurred variably from day 5 to 8 and correlated with the fold-rise rise in hemagglutination inhibition (HAI titers); r=0.91, p=0.006. H3-specific IgG ASC frequencies correlated less well, perhaps due to a mismatch of the H3 protein in the vaccine and that used in the Elispot assay. Peak frequencies of vaccine-specific and total-IgG ASCs were 0.3% and 0.8%, respectively, of peripheral blood mononuclear cells (PBMC). Peak TIV-, H1-, H3-, and total-IgG ASC frequencies were 1736+/-1133, 626+/-520, 592+/-463, and 4091+/-2019 spots/10(6) PBMC, respectively. Peak TIV-, H1-, and H3-specific IgG ASC of total-IgG ASC frequencies constituted 63%+/-21, 26%+/-10, 22%+/-17, respectively. CONCLUSION: After immunization with inactivated influenza vaccine the peak in influenza-specific ASC frequencies is variable but correlates well with the magnitude of protective HAI responses. (c) 2010 Elsevier Ltd. All rights reserved.
UNLABELLED: Upon vaccination, B cells differentiate into antibody secreting cells (ASCs) that migrate via the circulation to tissues. The kinetics of this response and the relationship of circulating ASCs to protective antibody titers have not been completely explored. METHODS:Influenza-specific and total-IgG ASCs were enumerated by Elispot and flow cytometry daily in the blood in 6 healthy adults after trivalent influenza vaccination (TIV). RESULTS: Peak H1-specific IgG ASC frequencies occurred variably from day 5 to 8 and correlated with the fold-rise rise in hemagglutination inhibition (HAI titers); r=0.91, p=0.006. H3-specific IgG ASC frequencies correlated less well, perhaps due to a mismatch of the H3 protein in the vaccine and that used in the Elispot assay. Peak frequencies of vaccine-specific and total-IgG ASCs were 0.3% and 0.8%, respectively, of peripheral blood mononuclear cells (PBMC). Peak TIV-, H1-, H3-, and total-IgG ASC frequencies were 1736+/-1133, 626+/-520, 592+/-463, and 4091+/-2019 spots/10(6) PBMC, respectively. Peak TIV-, H1-, and H3-specific IgG ASC of total-IgG ASC frequencies constituted 63%+/-21, 26%+/-10, 22%+/-17, respectively. CONCLUSION: After immunization with inactivated influenza vaccine the peak in influenza-specific ASC frequencies is variable but correlates well with the magnitude of protective HAI responses. (c) 2010 Elsevier Ltd. All rights reserved.
Authors: Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe Journal: Nat Rev Immunol Date: 2006-09-15 Impact factor: 53.106
Authors: Sanae Sasaki; Maria C Jaimes; Tyson H Holmes; Cornelia L Dekker; Kutubuddin Mahmood; George W Kemble; Ann M Arvin; Harry B Greenberg Journal: J Virol Date: 2006-10-18 Impact factor: 5.103
Authors: G R Noble; H S Kaye; W B Yarbrough; B K Fiedler; C J Reed; M B Felker; A P Kendal; W R Dowdle Journal: J Infect Dis Date: 1977-12 Impact factor: 5.226
Authors: Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman Journal: J Infect Dis Date: 2011-09-19 Impact factor: 5.226
Authors: Carl T D'Angio; Claire P Wyman; Ravi S Misra; Jessica L Halliley; Hongyue Wang; Julianne E Hunn; Caitlin M Fallone; F Eun-Hyung Lee Journal: Vaccine Date: 2017-08-12 Impact factor: 3.641
Authors: Katherine J L Jackson; Yi Liu; Krishna M Roskin; Jacob Glanville; Ramona A Hoh; Katie Seo; Eleanor L Marshall; Thaddeus C Gurley; M Anthony Moody; Barton F Haynes; Emmanuel B Walter; Hua-Xin Liao; Randy A Albrecht; Adolfo García-Sastre; Javier Chaparro-Riggers; Arvind Rajpal; Jaume Pons; Birgitte B Simen; Bozena Hanczaruk; Cornelia L Dekker; Jonathan Laserson; Daphne Koller; Mark M Davis; Andrew Z Fire; Scott D Boyd Journal: Cell Host Microbe Date: 2014-06-26 Impact factor: 21.023
Authors: F Eun-Hyung Lee; Jessica L Halliley; Edward E Walsh; Andrew P Moscatiello; Brittany L Kmush; Ann R Falsey; Troy D Randall; Denise A Kaminiski; Richard K Miller; Iñaki Sanz Journal: J Immunol Date: 2011-03-25 Impact factor: 5.422
Authors: Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy Journal: Expert Rev Vaccines Date: 2019-02-11 Impact factor: 5.217
Authors: Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci Journal: J Virol Date: 2013-03-13 Impact factor: 5.103
Authors: Tâm D Quách; Nely Rodríguez-Zhurbenko; Thomas J Hopkins; Xiaoti Guo; Ana María Hernández; Wentian Li; Thomas L Rothstein Journal: J Immunol Date: 2016-01-06 Impact factor: 5.422